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Background: The Philippines HIV epidemic is one of the fastest growing, globally. Infections among men who 20 
have sex with men (MSM) are rising at an alarming rate, necessitating targeted evidence-based interventions to 21 
reach epidemic control. Treatment as prevention is a key strategy to end AIDS, making it a priority to explore 22 
novel approaches to retain people living with HIV (PLHIV) in care, support adherence, and reach viral 23 
suppression. Methods: This cross-sectional analysis describes HIV-related risk behaviours and adherence to 24 
antiretroviral therapy (ART) in a population of HIV-positive patients at a clinic in Metro Manila, Philippines 25 
participating in the Philippines Connect for LifeTM cohort study. Results: Among 426 HIV-positive adults 26 
taking ART, 79% reported ≥95% adherence over the prior 30 days. Longer time on treatment was associated 27 
with reduced adherence to ART (adjusted odds ratio (AOR) = 0.87 per year, P = 0.027). Being in a 28 
serodiscordant relationship, in which the subject’s primary partner was HIV negative, increased adherence 29 
(AOR = 3.19, P = 0.006). Inconsistent condom use (AOR = 0.50, P = 0.103) and injection drug use (AOR = 30 
0.54, P = 0.090) are potentially associated with reduced adherence to ART. Patients used drugs and alcohol at 31 
significantly higher rates than the general population. Conclusions: The study found that patients in this setting 32 
require intervention to address treatment fatigue. Interventions to improve social support of PLHIV, as well as 33 
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harm-reduction approaches for drug and alcohol use, could improve adherence in this population, strengthening 34 
the test-and-treat strategy to control the epidemic. 35 
Keywords: adherence, antiretroviral therapy, Asia, evidence-based policy, harm reduction, HIV/AIDS, men 36 
who have sex with men, people living with HIV, Philippines. 37 
We conducted a study in the Philippines, where the HIV/AIDS epidemic is concentrated among young men who 38 
have sex with men (MSM), to better understand adherence to antiretroviral therapy (ART) among this key 39 
population. In our study population of 462 HIV-positive patients, predominantly young MSM, 79% of patients 40 
were adherent to their ART. We found that longer time on treatment led to lower adherence, and that social 41 
support and substance use were important factors. 42 
Introduction 43 
The Philippines has the fastest growing HIV/AIDS epidemic in the Asia–Pacific region.1–3 National 44 
surveillance data show that the number of new HIV cases in the Philippines has risen at an alarming 45 
rate during the past decade, with an increase from 311 cases identified in 2007 to 11 427 cases 46 
identified in 2018 – a 36-fold increase in new HIV diagnoses.4 According to the Joint United Nations 47 
Programme on HIV/AIDS (UNAIDS)’s surveillance reports, the Philippines’ progress towards 48 
reaching HIV/AIDS 90–90–90 goals is slow, with 67% of people living with HIV (PLHIV) aware of 49 
their status, 48% of those who know their status on treatment, and low coverage of viral load testing 50 
(<50%).5 51 
Young men who have sex with men (MSM) are the key population in this emerging epidemic. 52 
Early in the HIV epidemic, most diagnoses were among heterosexual females, especially sex workers. 53 
Today, 85% of new cases are in MSM, the median age of new cases in the Philippines is 28 years, and 54 
more than 80% of people living with HIV/AIDS in the Philippines are aged under 35 years.4 In 2015, 55 
a national surveillance survey found that HIV prevalence among MSM who practice anal sex was 6%, 56 
an increase from 3.3% in 2013.6–8 57 
As the burden of HIV increases, it is imperative that as many HIV-infected people as possible are 58 
diagnosed, started on treatment and successfully retained in care. Achieving adequate viral 59 
suppression through the use of antiretroviral therapy (ART) will be one of the key tools in ending the 60 
HIV epidemic in the Philippines. Unfortunately, widespread stigma, lack of knowledge, and barriers 61 
to accessing care pose a challenge to engaging patients in testing and then ensuring high levels of 62 
adherence to ART and retention in care.6,8,9 As in many developing countries, high rates of first-line 63 
treatment failure, loss to follow up, and suboptimal treatment adherence lead to poor outcomes for 64 
many HIV patients in the Philippines.10,11 65 
Evidence-based public health interventions are needed. However, a 2015 report by the World 66 
Health Organization (WHO) highlights that the body of HIV research conducted in the Philippines 67 
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has been limited,12 and a systematic review of the HIV risk studies in the Philippines through April 68 
2018 found only three publications that included data about the group most affected by HIV, MSM.13 69 
This study aims to describe the demographic profile, clinical characteristics, HIV-related risk 70 
behaviours, quality of life (QOL), and ART adherence levels in a population of HIV-positive 71 
individuals comprised primarily of MSM receiving treatment at the Sustained Health Initiatives of the 72 
Philippines (SHIP) Clinic in Metro Manila, Philippines. 73 
Methods 74 
Study design, participants, and setting 75 
A cross-sectional analysis was conducted using data from the baseline visit of a cohort study of 76 
patients at the SHIP clinic. The purpose of the larger cohort study was to evaluate the Connect for 77 
LifeTM mobile phone adherence support intervention. Data were collected from October 2016 to 78 
December 2018. 79 
The SHIP Clinic is a public–private partnership, low-cost, fee-for-service facility in Mandaluyong, 80 
Metro Manila, which has provided HIV treatment and a comprehensive package of primary healthcare 81 
services to more than 900 patients since it opened in 2012. SHIP is a satellite partner clinic of the 82 
STI/AIDS Guidance Intervention & Prevention Unit at the Philippine General Hospital. 83 
All patients starting or continuing on ART at the SHIP clinic who had a mobile phone and who 84 
spoke English (one of the two official languages in the Philippines and spoken fluently by nearly all 85 
of the patients from the study site) were eligible to participate in the study. Mobile phones were 86 
required because all patients who were enrolled would receive a mobile phone adherence intervention. 87 
The study coordinator approached patients during their routine clinic visits to provide information 88 
about the study and complete the informed consent process. 89 
Measures 90 
At the baseline study visit, the study coordinator collected demographic data and extracted medical 91 
history from the patient charts. Each participant completed a questionnaire on HIV-related 92 
knowledge, attitudes and practices (KAP) that was specific to the mobile phone adherence 93 
intervention and the WHO HIV Quality of Life questionnaire (WHO QOL-HIV BREF 94 
https://www.who.int/mental_health/publications/whoqol_hiv_bref.pdf). Patients who had taken ART 95 
before also completed an adherence questionnaire that was adapted from the AIDS Clinical Trials 96 
Group tools. All questionnaires were in English. The questionnaires were self-administered, with 97 
assistance from the study coordinator as requested. 98 
The self-reported adherence measure used a visual analogue scale (VAS) in which patients reported 99 
the proportion of ART doses taken in the prior 30 days from 0–100%. For ART to be effective, it 100 
should be taken consistently, and early studies reported that ≥95% adherence to ART was required to 101 
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achieve and maintain viral suppression.14,15 More recent studies have shown that virological 102 
suppression may be achieved with adherence levels <95%; however, this is dependent on the duration 103 
of treatment and the ART regimen.16–18 Therefore, in this analysis, those who took ≥95% of their ART 104 
doses were considered adherent, and <95% as non-adherent. 105 
Statistical analysis 106 
Descriptive data analysis was conducted to categorise the study population. Categorical variables 107 
were described with proportions and continuous variables were described with means and confidence 108 
intervals. We examined which characteristics of individuals were associated with adherence to ART 109 
of >95%. Crude odds ratios (ORs) were calculated with logistic regression to examine which 110 
demographic, behavioural, and clinical factors are related to self-reported adherence. Factors 111 
significant at P-value <0.1 on univariate analysis were included in a multivariate logistic regression 112 
analysis. Clinical variables were excluded from the multivariate if there was plausible reverse 113 
causality between ART adherence and the clinical characteristics (i.e. viral load suppression). Where 114 
possible, continuous variables were used in the multivariate model, whereas categorical variables 115 
were used for illustrative purposes in the crude OR descriptive analyses. Data analysis was conducted 116 
in Stata 15 (StataCorp LLC). 117 
Ethics 118 
Ethical clearance was obtained from the University of the Philippines Manila Research Ethics 119 
Board (protocol number 2016–265–01) and from the London School of Hygiene and Tropical 120 
Medicine (reference number 11631). All patients provided written consent before inclusion in the 121 
study. 122 
Results 123 
The cross-sectional analysis included 426 individuals. Variables were included in the following 124 
categories: Demographics, Clinical Characteristics, HIV Knowledge, Risk Behaviours, QOL, 125 
Adherence/Reasons for Missing Medication. 126 
At the time study enrolment began, the clinic had ~600 active patients. The study coordinator 127 
screened 485 patients as they presented during routine clinic visits, of whom 483 were eligible to 128 
participate in the study (one did not speak English, one did not have a Philippine mobile phone), and 129 
462 patients provided consent and were enrolled (of the 21 who declined, the most common reason 130 
was that they did not want to receive calls or SMS related to the intervention). Of 462 people enrolled 131 
in the Connect for Life intervention study, 31 were either ineligible to fill out the adherence 132 
questionnaire (initiated ART at the study baseline visit and had not started taking pills) or had missing 133 
questionnaires; as a result 426 individuals reported ART adherence, and are included in this analysis. 134 
All but one of these 426 subjects were male (99.8%), and almost all were MSM (419/426 or 98.4%). 135 
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The mean age was 32.4 years. University or post-graduate studies had been completed by 86% of 136 
participants (365/426), and 91% were employed (389/426), which reflects the higher socioeconomic 137 
status of patients who access private fee-for-service care. 138 
Perfect adherence of 100% of doses taken in the last 30 days was reported by 52.1% (222/426), 95–139 
99% was reported by 26.6% (113/426), adherence of 90–94% was reported by 12.7% (54/426), and 140 
adherence of <90% was reported by 8.7% (37/426) of patients. 141 
Medical history was extracted from patient files and included time on ART, nadir CD4 count, 142 
history of opportunistic infections (OIs), current and past ART medications and regimen changes, 143 
viral load suppression, and CD4 recovery. Various sociodemographic and clinical factors and their 144 
association with self-reported adherence to ART at ≥95% are reported in Table 1. 145 
Patient demographic and clinical characteristics 146 
Demographics 147 
There is evidence to suggest that low education level is associated with non-adherence (OR = 0.20, 148 
P = 0.031). There was no strong evidence of associations between employment/profession or age and 149 
adherence. 150 
Patients working in the Business Process Outsourcing (BPO) sector had lower adherence than other 151 
professions; this may be due to the varying shift times worked by call centre agents in this sector. 152 
Health workers had the highest adherence of any profession, followed by self-employed individuals. 153 
However, overall, there was no strong evidence of association between employment/profession and 154 
adherence. 155 
Relationship status appears to be an important factor in ART adherence. Of the 27.9% of subjects 156 
(119/426) who were in a relationship, most were in a serodiscordant relationship in which their 157 
primary partner was HIV negative. Those in serodiscordant partnerships had improved odds of 158 
adherence to ART compared with individuals who were not in a relationship (OR = 2.49). The 159 
evidence suggests that being in seroconcordant relationships (both HIV positive) and disclosure of 160 
HIV status to a trusted person may be also be factors that improve adherence; however, the sample 161 
size in this study was insufficient to reach these conclusions with confidence. 162 
Adherence and viral suppression 163 
Self-reported adherent patients were more likely to be virally suppressed (OR = 3.1, P = 0.016). 164 
Time on ART and virological failure 165 
Having been on ART for a longer time led to decreased adherence (0–6 months: OR = 1.00; 6 166 
months–1year: OR = 0.36; 1–2 years: OR = 0.43; 2–4 years: OR = 0.32; ≥4 years: OR = 0.25; P = 167 
0.013), which indicates that patients may be experiencing treatment fatigue over time. 168 
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In total, 27.9% of patients (119/426) had changed their ART medications at least once. Of those 169 
who changed regimens, 17.7% (21/119) had to change due to virological failure, whereas the 170 
remaining 98 people changed for other reasons such as intolerance/side-effects or depression 171 
worsened by efavirenz (EFV). Only 7.5% of patients (32/426) were on second-line lopinavir/ritonavir 172 
(LPV/r) or multiple resistance ART regimens, whereas 92.5% (394/426) were on efavirenz, 173 
nevirapine, or rilpivirine-based first-line ART regimens. 174 
CD4 and opportunistic infections history 175 
Most patients had a nadir CD4 count in the range of 200–350 cells/mm3, indicating that they were 176 
diagnosed and started on ART before disease progression to AIDS. However, 74 patients (17.4%) had 177 
nadir CD4 count <50 cells/mm3, indicating that they did not receive HIV diagnosis and treatment until 178 
they were already severely immune-compromised. Only 51.5% (206/400) of patients who had a nadir 179 
CD4 count <500 cells/mm3 had reached CD4 recovery back to levels <500 cells/mm3. 180 
History of OI was common, with 61% of patients (260/426) having one or more potential OIs 181 
recorded in their complete medical history. Pnuemocystis pneumonia (PCP) history was recorded in 182 
the medical history of 6% of patients (27/426), and 5% had a history of thrush (20/426). Hepatitis B at 183 
11% (46/426) and tuberculosis (TB) history at 18% (76/426) are similar to the overall population rates 184 
of these diseases, which are endemic to the Philippines.19,20 Hepatitis C prevalence was 0.7% in our 185 
cohort (3/426), which is also similar to the general population rate.19 Over 13% of patients (57/426) 186 
had a history of syphilis and 39% (166/426) had had another sexually transmissible infection (STI). 187 
There was no evidence of an association between ART adherence and nadir CD4, CD4 recovery, or 188 
OI history. 189 
Risk behaviours 190 
The association between risk behaviours and ART adherence is outlined in Table 2. 191 
Sexual partners and condom use 192 
The mean number of sex partners for participants in the last 6 months was 2.73. Among participant 193 
21.8% reported zero partners (93/426), 32.2% reported one partner (137/426), 23.2% reported 194 
between two and nine partners (99/426), and 4.2% reported >10 partners (18/426), whereas 20.9% 195 
(89/426) of participants did not provide an answer on the questionnaire. Only 6% (25/426) of the 196 
patients reported having ever engaged in transactional sex, and of those, only two participants had had 197 
transactional sex within the last 6 months. In the study population, 41.3% (176/426) reported they 198 
always use condoms and 35.4% (151/426) use them some of the time or most of the time. This 199 
inconsistent condom use was associated with non-adherence to ART (OR = 0.48, P = 0.007); 200 
however, individuals who reported never using condoms did not have reduced odds of ART 201 
adherence. 202 
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Drug and alcohol use 203 
In our study population, 9.4% (40/426) used ‘shabu’ (methamphetamine hydrochloride), 8.0% 204 
(34/426) used cannabis, 4.5% (19/423) used prescription drugs for non-medical use, and 1.4% (6/426) 205 
used inhalants (e.g. ‘rugby’ or ‘poppers’) within the last 3 months, and 0.7% (3/426) of respondents 206 
did not complete the substance use portion of the questionnaire. Injecting drug users (IDU) were 207 
12.2% (52/426) of the study population; 52 who had ever injected drugs and 28 who had done so 208 
within the last 3 months. Among IDUs, the odds of ART adherence were lower (IDU ever OR = 0.46, 209 
P = 0.015; IDU in last 3 months OR = 0.38, P = 0.019). Only two individuals reported ever having 210 
shared needles for injecting drugs. There was no association between adherence and non-injecting 211 
drug use. 212 
Although 30.5% (130/426) of patients abstained from alcohol, 37.3% (159/426) engaged in heavy 213 
episodic drinking in the last 30 days. Problem drinking, defined as two or more episodes of heavy 214 
episodic or ‘binge’ drinking (>five drinks) in the last month or >14 drinks per week on average,21,22 215 
was prevalent in 13.4% (57/426) of the study population. Alcohol use did not have an association with 216 
ART adherence. 217 
Quality of life 218 
The WHO HIV-QL31 scores QOL in six domains, a maximum of 20 points per domain and a total 219 
score of 120. The mean for each of the six domains and the total WHO HIV-QL31 score are as 220 
follows: Physical 15.21; Psychological 15.04; Level of Independence 15.54; Social Relationships 221 
15.01; Environmental 13.43; and Spirituality 14.44. The domain with the lowest overall score was 222 
Environment, which measures aspects such as safety and security; access to health care; financial 223 
resources; opportunities for learning and for leisure; and physical environment 224 
(pollution/noise/traffic/climate).23 225 
The mean QOL score in the cohort was 88.68 (95% CI 87.46–89.89). Just under half (46.5%) of the 226 
426 participants had an overall QOL score of ≥90, which represents a high QOL, and 52.3% percent 227 
had a medium QOL with a score between 60 and 89. Only five patients (1.3%) had a QOL score <60. 228 
One patient did not complete the QOL questionnaire. There was no significant association between 229 
ART adherence and overall QOL (Table 2) or individual QOL domains (data not shown). 230 
Knowledge of HIV 231 
There was evidence of an association between knowledge of HIV, as scored on a 16-item 232 
questionnaire, and ART adherence. There is an association between scoring 80% and 89% on the HIV 233 
knowledge questionnaire and lower adherence (OR = 0.49, P = 0.044). This association does not hold 234 
for those scoring >90% and the reason for the association is unclear, warranting further investigation. 235 
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Adherence/reasons for missing medication 236 
There were 228 study participants who reported having missed medications at any point in the past; 237 
the reasons they reported for ever missing medications are detailed in Figure 1. The most common 238 
reasons for missing medications were that that the patient was busy, they forgot, fell asleep, was away 239 
from home, or had a change in their daily routine. Stigma is also a factor affecting adherence, as 44% 240 
of patients who had skipped a pill at some point did so because they did not want to be seen taking 241 
medications. Issues around side-effects, toxicity, and pill burden were the least likely contributors to 242 
non-adherence. 243 
Multivariate logistic regression model for adherence to antiretroviral therapy 244 
In the final multivariate logistic regression model (Table 3), time on ART (adjusted OR (AOR) = 245 
0.87 per year, P = 0.027 seroconcordant/serodiscordant relationship status (P = 0.006)), and 246 
knowledge score (P = 0.047) were associated with ART adherence. Injection drug use and 247 
inconsistent condom use (using condoms sometimes or most of the time) may also be related to 248 
adherence, whereas the study sample may have been too small to evaluate these factors. 249 
Discussion 250 
Twenty-one percent (91/426) of the study participants reported suboptimal adherence. By 251 
comparison, ~37% of patients globally report suboptimal adherence to ART,17,24 and in the regional 252 
Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) cohort (which includes 253 
a large treatment site in the Philippines), 32% of 1316 patients reported suboptimal adherence of 254 
<100%.11 As expected, self-reported adherent patients were more likely to be virally suppressed, 255 
which indicates that patient self-report of adherence or non-adherence accurately reflects their pill-256 
taking behaviour. 257 
The study found that people who had been on treatment longer were less likely to be adherent to 258 
their ART. This finding is contrary to the TREAT Asia regional cohort study, which found 26% of 259 
patients self-reported suboptimal adherence levels during their first 6 months of treatment, and that 260 
adherence improved over time from initiation to 24 months.11 These contradictory findings warrant 261 
further investigation. Reasons for non-adherence in this study were largely situational factors, habits, 262 
and routines, whereas clinical issues such as side-effects and pill burden were less likely to impact 263 
adherence in this population. 264 
Condom use in this study population was comparable to the general MSM population in the 265 
Philippines – 41.3% (146/405) of the sexually active SHIP population study participants always use 266 
condoms and 35.5% (151/405) use condoms most or some of the time, whereas the 2013 surveillance 267 
data showed 40.7% condom use at last anal sex among MSM.8,25 Inconsistent condom use (using 268 
condoms sometimes or most of the time) may be associated with ART non-adherence, which suggests 269 
that motivating factors and abilities that enable a patient to adhere to ART could also be the same 270 
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factors that lead to consistent condom use. The average total number of sex partners in the last 6 271 
months was 2.14, which is lower than has been reported in other surveillance of MSM in the 272 
Philippines;8,25 this may indicate that MSM reduce their sexual activity after becoming HIV positive 273 
and starting ART, a question that warrants further investigation. 274 
Relationship status appears to be an important factor in ART adherence. Patients in serodiscordant 275 
relationships were more likely to adhere to ART. The data suggest that being in a relationship, 276 
whether seroconcordant or serodiscordant, is better than being single when it comes to ART 277 
adherence, and that disclosure of one’s HIV-positive status to a trusted person can also lead to better 278 
outcomes. These findings emphasise the important role of partner, family and social support for HIV 279 
patients in order to achieve good clinical outcomes. 280 
Another key finding in this study is that the study participants used drugs and alcohol at rates five- 281 
to 10-fold higher than the general population. In the Philippines general population, 44.7% of males 282 
abstain from alcohol and 3.5% of males engage in heavy episodic drinking,26 whereas in our study 283 
population, only 30.5% abstained and 37.3% had engaged in heavy episodic drinking in the last 30 284 
days. According to the United Nations Office on Drugs and Crime, 1.1% of Filipinos use ‘shabu’ 285 
(methamphetamine hydrochloride) and 1.6% use cannabis.27 In our study population, 9.9% had used 286 
‘shabu’ and 7.7% used cannabis within the last 3 months. Methamphetamine use is strongly 287 
associated with high-risk sexual behaviour and HIV acquisition,28 and is commonly used by MSM in 288 
chemsex or ‘Partee ‘n’ Play’ activities. Compounding these risks, evidence-based HIV prevention 289 
services are not widely available in the Philippines – condom distribution is restricted,29,30 pre- and 290 
post-exposure prophylaxis are not widely available, except through very limited pilot projects, and 291 
syringe exchange is illegal under the current administration’s interpretation of the Philippines’ 292 
Dangerous Drugs Act of 2002. 293 
Limitations 294 
This study is limited by several factors. First, adherence and risk behaviours were self-reported, and 295 
the responses are subject to social desirability bias. However, adherence was strongly associated with 296 
viral load suppression, and risk behaviours were not significantly lower than the general population 297 
(and in many cases much higher), which suggests that the self-report method was generally accurate. 298 
Furthermore, the generalisability of study data from the SHIP clinic population is limited. Due to the 299 
higher socioeconomic status and education levels of the SHIP clinic patients, and due to the fact that it 300 
is a fee-for-service clinic, the cohort may not be representative of MSM in the Philippines more 301 
broadly. Apart from employment, education, and high HIV knowledge levels, other demographic 302 
factors (age, clinical outcomes, risk profile) align with other published data on MSM and people 303 
living with HIV from the country.7,8,25,31 Ongoing follow up of the SHIP Connect for Life study cohort 304 
will provide further details about incidence of OIs, retention in care, and ART adherence. 305 
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Conclusions 306 
This study provides an in-depth analysis of demographic, clinical, and behavioural characteristics 307 
of MSM living with HIV in the Philippines, which can improve understanding of the country’s 308 
epidemic and may be used to inform tailored prevention and treatment interventions. 309 
Factors found to be associated with adherence to HIV treatment were time on ART, being in a 310 
serodiscordant relationship in which the person’s main partner is HIV negative, and HIV knowledge 311 
level. 312 
The issue of treatment fatigue warrants further investigation and should be addressed through 313 
implementation of tailored adherence interventions. Clinicians and other service providers should 314 
prioritise counselling and interventions to improve family and social support for HIV patients. There 315 
is also an unexplored opportunity for harm-reduction interventions among HIV-positive and HIV-316 
negative MSM who use drugs and alcohol. 317 
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Fig. 1. Reasons for missing medication (n = 228). 425 
 426 
 427 
Table 1. Patient characteristics 428 
OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy 429 
Patient characteristics Total Adherent ≥95% 
Non-adherent 
<95%   
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 (n = 
426) 
 (n = 
335) 
 (n = 
91) 




 n (%) n (%) n (%) 
  
Gender         
 Male 425 99.77 334 78.59 91 21.41 –  
 Female 1 0.23 1 100.00 0 0.00 –  
  
 
      
Age (years)         
 18–24 19 4.46 17 89.47 2 10.53 1.00 
0.498 
 25–29 119 27.93 95 79.83 24 20.17 0.47 (0.10–2.16) 
 30–39 245 57.51 188 76.73 57 23.27 0.39 (0.09–1.73) 
 ≥40 43 10.09 35 81.40 8 18.60 0.51 (0.10–2.69) 
  
 
      
Education         





19 4.46 15 78.95 4 21.05 1.11 (0.36–3.44) 
 College/University 316 74.18 244 77.22 72 22.78 1.00 
 Post-Graduate 49 11.50 44 89.80 5 10.20 2.60 (0.99–6.79) 
 Unknown/Did not 
report 
32 7.51 28 87.50 4 12.50 2.07 (0.70–6.08) 
         
Employment         
 Business Process 
Outsourcing (BPO) 




38 8.92 34 89.47 4 10.53 2.83 (0.90–8.89) 
 Health Worker 16 3.76 15 93.75 1 6.25 5.00 (0.62–40.06) 
 ProfessionalA 234 54.93 182 77.78 52 22.22 1.17 (0.66–2.07) 
 Student 13 3.05 10 76.92 3 23.08 1.11 (0.28–4.41) 
 Unemployed 37 8.69 28 75.68 9 24.32 1.04 (0.42–2.53) 
  
 
      
Sexual orientation         
 Bisexual 128 30.05 96 75.00 32 25.00 1.00 
0.467 
 Heterosexual 7 1.64 6 85.71 1 14.29 2.00 (0.23–17.25) 
 Homosexual 290 68.08 232 80.00 58 20.00 1.33 (0.81–2.18) 
 Pansexual 1 0.23 1 100.00 0 0.00 – 
 
  
      
Civil status         
 Married/Common-
law partner 
21 4.93 19 90.48 2 9.52 1.00 
0.282  Single 404 94.84 315 77.97 89 22.03 0.47 (0.11–2.10) 
 Unknown/Did not 
report 
1 0.23 1 100.00 0 0.00 – 
 
 
       
Serodiscordant         
 Not in a 
relationship 










71 16.67 63 88.73 8 11.27 2.49 (1.13–5.48)* 
 Unknown/Did not 
report 
45 10.56 32 71.11 13 28.89 0.78 (0.39–1.58) 
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Disclosure of HIV 
status to family/friend 
        
 Disclosed 137 32.16 113 82.48 24 17.52 1.00 
0.181 
 Not disclosed 207 48.59 155 74.88 52 25.12 0.63 (0.37–1.09) 
 Unknown/Did not 
report 
82 19.25 67 81.71 15 18.29 0.95 (0.47–1.93) 
 
  
      
Time on ART, years 
(mean) 
2.77 years (95% 
CI 2.58–2.96) 
2.61 (2.40–2.82) 3.35 (2.90–3.79)   
 0–6 months 46 10.80 42 91.30 4 8.70 1.00 
0.078 
 6 months – 1 year 38 8.92 30 78.95 8 21.95 0.36 (0.10–1.3) 
 1–2 years 83 19.48 68 81.93 15 18.07 0.43 (0.13–1.39)* 
 2–4 years 162 38.03 125 77.16 37 22.84 0.32 (0.11–0.96)* 
 >4 years 97 22.77 70 72.16 27 27.84 0.25 (0.08–0.75)* 
         
Nadir CD4 
(cells/mm3) (Mean) 
245 (95% CI 229–
260) 
246 (227–263) 244 (212–275)   
 0–200 163 38.26 132 80.98 31 19.02 1.00 
0.065  200–499 237 54.76 179 75.53 58 24.47 0.72 (0.44–1.18) 
 500+ 26 6.93 24 92.31 2 7.69 2.82 (0.63–12.56) 
         
Viral Suppression         
 Undetectable 257 92.45 207 80.54 50 19.46 3.11 (1.24–7.77) 
0.020
* 
 Detectable (>500 
copies) 
21 7.55 12 57.14 9 42.86 1.00 
*Adherence is self-reported over the last 30 days. 430 
A‘Professional’ is a broad category that includes patients who work as corporate or government employees, and 431 
workers in the education, IT, science, engineering, media, and sales and marketing sectors. 432 
Table 2.  Association between risk behaviours and antiretroviral therapy adherence   433 
OR, odds ratio; CI, confidence interval; N/A, not applicable 434 













 n (%) n (%) n (%)  
 
        
 
Condom usage in 
last 6 months        
 




of the time 151 35.45 106 70.20 45 29.80 
0.48 (0.29–
0.82)* 
 Never 78 18.31 66 84.62 12 15.38 
1.13 (0.54–
2.35) 
 N/A (not 
sexually active) 21 4.93 17 80.95 4 19.05 
0.87 (0.27–
2.78) 
         
Transactional sex         
 Never had 
transactional sex 399 93.66 314 78.70 85 21.30 1.00 
0.662 
 Ever had 
transactional sex 25 5.87 20 80.00 5 20.00 
1.08 (0.39–
2.97) 
Publisher: CSIRO; Journal: SH:Sexual Health 
 Article Type: Original Paper; Volume: ; Issue: ; Article ID: SH20028 
 DOI: 10.1071/SH20028; TOC Head:  
Page 16 of 17 
 
Unknown/Refused 2 0.47 1 50.00 1 50.00 
0.27 (0.02–
4.37) 
         
Drug use in last 3 
months        
 
 No 356 83.57 282 79.21 74 20.79 1.00 
0.519 
 Yes 70 16.43 53 75.71 17 24.29 
0.82 (0.45–
1.50) 
         
Injection drug use 
ever        
 
 No 374 87.79 301 80.48 73 19.52 1.00 
0.018* 
 Yes 52 12.21 34 65.38 18 34.62 
0.46 (0.25–
0.86)* 
         
Heavy alcohol use         
 
 No 363 86.43 289 79.61 74 20.39 1.00 
0.201 
 Yes 57 13.57 41 71.93 16 28.07 
0.66 (0.35–
1.23) 
         
Quality of life 
(QOL) 







 High (90–120) 183 46.45 148 80.87 35 19.13 1.00 
0.427 
 Medium (60–












         
HIV knowledge 









         
 <80 95 22.35 80 84.21 15 15.79 1.00 
0.044* 
 80–89 
163 38.35 118 72.39 45 27.61 
0.49 (0.26–
0.94)* 
 ≤90 167 39.29 136 81.44 31 18.56 
0.82 (0.42–
1.62) 
Table 3. Multivariate logistic regression analysis of factors associated with antiretroviral 435 
therapy (ART) adherence 436 
OR, odds ratio; CI, confidence interval; N/A, not applicable 437 
Variable Adjusted OR 95% CI P-value 
Education   
 
 Elementary or less 0.42 (0.10–1.75) 
0.084 
 High School/Vocational 1.16 (0.36–3.82) 
 College/University 1.00  
 Post-Graduate 2.40 (0.87–6.63) 
 Unknown 2.57 (0.81–8.16) 
    
Serodiscordant   
 
 N/A not in a relationship 1.00  
0.006* 
 Seroconcordant relationship (both HIV+) 2.37 (0.95–5.93) 
 Serodiscordant relationship (partner is HIV–) 3.19 (1.39–7.35) 
 Unknown 0.81 (0.37–1.79) 
    
Time on ART, years 0.87 (0.77–0.98) 0.027* 
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Nadir CD4 (cells/mm3)    
 0–200 1.00  
0.1334  200–499 0.78 (0.46–1.33) 
 500+ 2.87 (0.60–13.61) 
    
Condom usage (in last 6 months)   
 
 Always 1.00  
0.103 
 Sometimes/Most of the time 0.50 (0.28–0.89) 
 Never 0.81 (0.24–2.75) 
 N/A (not sexually active) 0.94 (0.43–2.06) 
    
Injection drug use (in last 3 months) 0.54 (0.27–1.09) 0.090 
    
HIV Knowledge Score (mean, %)    
 <80 1.00  
0.047*  80–89 0.47 (0.23–0.94) 
 ≤90 0.81 (0.39–1.67) 
 438 
 439 
 440 
